Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy : a randomized proof-of-concept clinical trial University of Antwerp
Robert Colebunders, Patrick Suykerbuyk, An Hotterbeekx, Joseph Nelson Siewe Fodjo, M. Mandro, G. Abhafule, D. Rossy, J.M. Jakwong, J. Meganck, D. Mukendi, A. Dusabimana, S. Menon, S. Haesendonckx, R. Lokonda, F. Nyisi
Open dataset for a proof-of-concept randomized clinical trial with a four month follow-up period was conducted to investigate whether ivermectin had an added value in decreasing the frequency of seizures in onchocerciasis-infected persons with epilepsy (PWE). The 90 PWE with epilepsy were randomly allocated to the treatment arms: phenobarbital + ivermectin (n = 44) or phenobarbital alone (n = 46). Two weeks after randomization, a follow-up visit was scheduled to assess the early treatment outcomes and potential side effects of AED. After the second week visit, PWE had to report to the health ...